This technology employs AAV gene targeting to disrupt the Caspase-3 genomic locus in HCT116 colon cancer cells, generating caspase-3 null cell lines. Two distinct clones have been developed and thoroughly characterized, demonstrating features such as complete deletion of both alleles and enhanced sensitivity to specific anticancer agents. These cell lines serve as precise tools to investigate apoptosis and cell death signaling pathways, offering researchers a reliable in vitro model for studying the fundamental mechanisms underlying programmed cell death in cancer.